AquaBounty Technologies is a biotechnology and aquaculture company based in Maynard, Massachusetts, United States. The company is notable for its research and development of genetically modified fish.[2] It aims to create products that aim to increase the productivity of aquaculture.[3] As of 2020, sale of the company's AquAdvantage salmon has been approved in Canada and the United States.
 | |
| Nasdaq: AQB Russell Microcap Index component | |
| Industry | Biotechnology Aquaculture |
| Founded | 1991[1] |
| Headquarters | Maynard, Massachusetts[1] |
Key people | David Frank (Interim CEO) |
| Parent | TS Aquaculture, LLC |
| Website | aquabounty |
History
editThe underlying genetic technology that accelerates the growth and reduces the time to market for the AquAdvantage salmon was developed in 1989 at Memorial University in Newfoundland, Canada. In 2003, the first regulatory study of the fish was submitted in the U.S. to the Food and Drug Administration (FDA), who ruled that the fish were safe to eat and posed no threat to the environment when farmed in land-based aquaculture farms. In 2012, a submission was made to Health Canada to allow the sale of the genetically modified fish in Canada and the application was subsequently approved.[4] AquAdvantage salmon received FDA approval in 2015 and the first U.S. harvest of salmon occurred in 2020 at their Indiana-located aquafarm. As of 2022, a production facility is in construction in Ohio.[5]
In December 2024, CEO Dave Melbourne resigned from the company. Days later, the company announced it would wind down operations at its Bay Fortune site, its last operating farm. Interim CEO David Frank said the company did not have sufficient liquidity to maintain operations at the facility.[6]
Products
editThe company has developed hybrid salmon, trout, and tilapia designed to grow faster than traditional fish. Only the salmon has progressed to government (Canada, United States) approvals[7] and are the first genetically modified animals approved for consumption.[8] Their hybrid Atlantic salmon incorporates a gene from a Chinook salmon, which bears a single copy of the stably integrated α-form of the opAFP-GHc2 gene construct at the α-locus in the EO-1α line (Ocean Pout AKA Eel).[9] AquaBounty has patented and trademarked this fish as the AquAdvantage salmon, a sterile Atlantic salmon female that can grow to market size in half the time of conventional salmon.[10]
The company was reported to have made its first sale of 4.5 metric tons (4.4 long tons; 5.0 short tons) of AquaAdvantage salmon to Canadian customers in July 2017.[11] Sales in the U.S. started May 2021.[12]
Finances
editIn 2012, a New York Times article reported the finances of AquaBounty were not in good shape and the company had to reduce staff from 27 to 12.[13] In March 2012, AquaBounty raised US$2 million in new capital, but this would only last until the end of the year.[13] Georgian investor Kakha Bendukidze owned 47.6% of the company's stock before selling to American synthetic biology firm Intrexon in October 2012. Intrexon put up $500,000 in bridge financing and offered to buy the rest of the company.[10][14] Intrexon acquired majority ownership of AquaBounty in 2013.[15] In 2019 Intrexon sold AquaBounty - which continues as a publicly held company - to TS Aquaculture, LLC, a privately held company managed by Third Security, LLC, a venture capital firm led by former Intrexon Chairman & CEO Randal J. Kirk.[16]
References
edit- ^ a b "Company & History". Archived from the original on 2011-06-28. Retrieved 2011-03-18.
- ^ "Canada Approves Sale of Genetically Modified Salmon". Democracy Now!.
- ^ "AquaBounty Technologies Company Overview". Bloomberg Businessweek. Archived from the original on 2012-10-11. Retrieved 2011-03-18.
- ^ Canada, Health (2016-05-19). "AquAdvantage Salmon". aem. Retrieved 2021-01-12.
- ^ "About Us". aquabounty.com. Retrieved 2022-06-08.
- ^ Ryan, Carolyn (2024-12-11). "AquaBounty cutting 'substantially all' staff, plans to shut down P.E.I. salmon hatchery". CBC News. Retrieved 2024-12-12.
- ^ Chesto, Jon (March 24, 2019). "AquaBounty's genetically engineered fish swim closer to sales in US". Boston Globe. Retrieved 25 March 2019.
- ^ "Like salmon? They're now the first genetically modified animals approved for consumption". USA TODAY. Retrieved 2021-01-11.
- ^ Staveley, Jane P. (25 August 2010). "Environmental Assessment for AquAdvantage Salmon" (PDF). Food and Drug Administration. Archived from the original (PDF) on 26 September 2012. Retrieved 2012-10-03.
- ^ a b Pollack, Andrew (December 21, 2012). "Engineered Fish Moves a Step Closer to Approval". The New York Times.
- ^ Waltz,Nature, Emily. "First Genetically Engineered Salmon Sold in Canada". Scientific American. Retrieved 2017-08-08.
- ^ Smith, Casey (21 May 2021). "Genetically modified salmon head to US dinner plates". AP News. Retrieved 6 August 2021.
- ^ a b Pollack, Andrew (21 May 2012) An Entrepreneur Bankrolls a Genetically Engineered Salmon. The New York Times, Retrieved 3 October 2012
- ^ "Delays put question mark over GM salmon as development company receives bid". Fishupdate.com. December 10, 2012. Archived from the original on January 21, 2013.
- ^ Jacob Bunge (15 December 2015) Firm Bets on Biotech That Changes How Food Is Produced. The Wall Street Journal, retrieved 30 January 2016
- ^ House, Douglas G (31 October 2019). "Intrexon sells AquaBounty stake to CEO-affiliated aquaculture business". Seeking Alpha. Retrieved 2 December 2020.
External links
edit | This fishing-related article is a stub. You can help Wikipedia by expanding it. |